当前位置：
X-MOL 学术
›
Drug Des. Dev. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Interaction of Analgesic Effects of Dezocine and Sufentanil for Relief of Postoperative Pain: A Pilot Study
Drug Design, Development and Therapy ( IF 4.7 ) Pub Date : 2020-11-03 , DOI: 10.2147/dddt.s270478 He Zhu 1 , Yaobing Chen 2 , Shaoqiang Huang 2 , Xingfeng Sun 2
Drug Design, Development and Therapy ( IF 4.7 ) Pub Date : 2020-11-03 , DOI: 10.2147/dddt.s270478 He Zhu 1 , Yaobing Chen 2 , Shaoqiang Huang 2 , Xingfeng Sun 2
Affiliation
Purpose: The combination of dezocine and sufentanil is often used for postoperative analgesia in China and other areas, but the interaction of both two drugs is still unclear. The purpose of this study was to evaluate the interaction of the analgesic effects of dezocine and sufentanil in the patients after gynecological laparoscopic surgery.
Patients and Methods: We conducted a prospective, randomized, double-blinded clinical trial. A total of 150 patients were divided into 5 groups (30 in each group) in the post-anesthesia care unit, namely, dezocine group (Group D), sufentanil group (Group S) and dezocine mixed sufentanil groups (Group DS1-3). In group D and S, the initial dose of dezocine or sufentanil was 5mg and 5μg intravenously, respectively. In Group DS1, the initial dose was dezocine 5mg × 3/4 and sufentanil 5μg × 1/4. In Group DS2, the initial dose was dezocine 5mg × 1/2 and sufentanil 5μg × 1/2. In Group DS3, the initial dose was dezocine 5mg × 1/4 and sufentanil 5μg × 3/4.
Results: The median effective dose (ED50) of dezocine and sufentanil alone was 3.92 (95% confidence interval (CI) 3.01∼ 4.64) mg and 3.71 (95% CI 2.78∼ 4.39) μg, respectively. The isobolographic analysis showed that the combination of dezocine and sufentanil at 1:3, 1:1 or 3:1 appeared in the additive line.
Conclusion: In conclusion, when simultaneously administered intravenously, combined dezocine and sufentanil produce an additive effect for relieving the acute nociception after gynecological laparoscopic surgery.
Keywords: dezocine, sufentanil, analgesia, intravenous, laparoscopy
中文翻译：
地佐辛和舒芬太尼镇痛作用缓解术后疼痛的相互作用：一项初步研究
目的：地佐辛与舒芬太尼联合应用在国内及其他地区常用于术后镇痛，但两种药物的相互作用尚不清楚。本研究的目的是评估地佐辛和舒芬太尼在妇科腹腔镜手术后镇痛作用中的相互作用。
患者和方法：我们进行了一项前瞻性、随机、双盲临床试验。将150例患者分为5组（每组30例）在麻醉后监护室，即地佐辛组（D组）、舒芬太尼组（S组）和地佐辛混合舒芬太尼组（DS1-3组） . D组和S组地佐辛或舒芬太尼的初始剂量分别为静脉注射5mg和5μg。DS1组初始剂量为地佐辛5mg×3/4和舒芬太尼5μg×1/4。DS2组初始剂量为地佐辛5mg×1/2和舒芬太尼5μg×1/2。DS3组初始剂量为地佐辛5mg×1/4和舒芬太尼5μg×3/4。
结果：单独使用地佐辛和舒芬太尼的中位有效剂量 (ED50) 分别为 3.92 (95% CI 3.01∼4.64) mg 和 3.71 (95% CI 2.78∼ 4.39) μg。等线图分析显示，地佐辛和舒芬太尼以1:3、1:1或3:1的组合出现在添加线中。
结论：综上所述，当同时静脉给药时，地佐辛和舒芬太尼联合用药对减轻妇科腹腔镜手术后的急性伤害感受产生累加作用。
【关键词】：地佐辛 舒芬太尼 镇痛 静脉注射 腹腔镜
更新日期：2020-11-03
Patients and Methods: We conducted a prospective, randomized, double-blinded clinical trial. A total of 150 patients were divided into 5 groups (30 in each group) in the post-anesthesia care unit, namely, dezocine group (Group D), sufentanil group (Group S) and dezocine mixed sufentanil groups (Group DS1-3). In group D and S, the initial dose of dezocine or sufentanil was 5mg and 5μg intravenously, respectively. In Group DS1, the initial dose was dezocine 5mg × 3/4 and sufentanil 5μg × 1/4. In Group DS2, the initial dose was dezocine 5mg × 1/2 and sufentanil 5μg × 1/2. In Group DS3, the initial dose was dezocine 5mg × 1/4 and sufentanil 5μg × 3/4.
Results: The median effective dose (ED50) of dezocine and sufentanil alone was 3.92 (95% confidence interval (CI) 3.01∼ 4.64) mg and 3.71 (95% CI 2.78∼ 4.39) μg, respectively. The isobolographic analysis showed that the combination of dezocine and sufentanil at 1:3, 1:1 or 3:1 appeared in the additive line.
Conclusion: In conclusion, when simultaneously administered intravenously, combined dezocine and sufentanil produce an additive effect for relieving the acute nociception after gynecological laparoscopic surgery.
Keywords: dezocine, sufentanil, analgesia, intravenous, laparoscopy
中文翻译：
地佐辛和舒芬太尼镇痛作用缓解术后疼痛的相互作用：一项初步研究
目的：地佐辛与舒芬太尼联合应用在国内及其他地区常用于术后镇痛，但两种药物的相互作用尚不清楚。本研究的目的是评估地佐辛和舒芬太尼在妇科腹腔镜手术后镇痛作用中的相互作用。
患者和方法：我们进行了一项前瞻性、随机、双盲临床试验。将150例患者分为5组（每组30例）在麻醉后监护室，即地佐辛组（D组）、舒芬太尼组（S组）和地佐辛混合舒芬太尼组（DS1-3组） . D组和S组地佐辛或舒芬太尼的初始剂量分别为静脉注射5mg和5μg。DS1组初始剂量为地佐辛5mg×3/4和舒芬太尼5μg×1/4。DS2组初始剂量为地佐辛5mg×1/2和舒芬太尼5μg×1/2。DS3组初始剂量为地佐辛5mg×1/4和舒芬太尼5μg×3/4。
结果：单独使用地佐辛和舒芬太尼的中位有效剂量 (ED50) 分别为 3.92 (95% CI 3.01∼4.64) mg 和 3.71 (95% CI 2.78∼ 4.39) μg。等线图分析显示，地佐辛和舒芬太尼以1:3、1:1或3:1的组合出现在添加线中。
结论：综上所述，当同时静脉给药时，地佐辛和舒芬太尼联合用药对减轻妇科腹腔镜手术后的急性伤害感受产生累加作用。
【关键词】：地佐辛 舒芬太尼 镇痛 静脉注射 腹腔镜
京公网安备 11010802027423号